Ono Pharmaceutical's vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval
Ono Pharmaceutical, one of the largest pharmaceutical companies in Japan headquartered in Chuo-ku, Osaka, has received approval from the US Food and Drug Administration for its kinase inhibitor Romvimza (vimseltinib) to treat tenosynovial giant cell tumour …